Top Markets
#1 Black Phoenix Black Phoenix +17,837.96%
#2 Cash Dog in Hood Cash Dog in Hood +6,493.59%
#3 AgentFun.AI AgentFun.AI +54.83%
#4 up up +49.01%
#5 Arrow Arrow +48.53%
#6 Quai Network Quai Network +39.70%
#7 Octra Octra +37.04%
#8 Derive Derive +34.20%
#9 Block Street Block Street +31.33%
#10 B3 (Base) B3 (Base) +31.22%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Theranexus Société Anonyme Theranexus Société Anonyme

Theranexus Société Anonyme

ALTHX
Rank in Stocks #15061
Theranexus société anonyme, a biopharmaceutical company, develops drug... Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Share Price
$4.66
Market Cap
$43.92M
Change (1 day)
-0.63%
Change (1 year)
338.04%
Country
FR
Trade Theranexus Société Anonyme (ALTHX)

Category

Healthcare
Revenue for Theranexus Société Anonyme (ALTHX)
Revenue in Dec 2025 TTM: $958.56K
According to Theranexus Société Anonyme latest financial reports the company's current revenue (TTM) is $958.56K. In 2023 the company made a revenue of $327.58K a decrease compared to the revenue in the year 2022 that was $445.05K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Theranexus Société Anonyme from 2015 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $958.56K -59.66%
2024 $2.38M 625.31%
2023 $327.58K -26.39%
2022 $445.05K 64,912.44%
2021 $684.56 -99.81%
2020 $358.80K -43.29%
2019 $632.64K 396.28%
2018 $127.47K -28.14%
2017 $177.38K 86.15%
2016 $95.29K -84.37%
2015 $609.53K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 5,429,475.67%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 1,278,390.46%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 1,556,359.45%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 947,390.82%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 656,137.28%
NL